Chemours (CC) Cash & Equivalents (2015 - 2026)

Chemours has reported Cash & Equivalents for 12 years, with the latest figure at $671.0 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 33.67% year-over-year to $671.0 million in Q2 2026; TTM through Jun 2026 was $671.0 million, a 33.67% increase from a year earlier, with the FY2025 full-year figure at $670.0 million, down 6.03% from the prior year.
• Cash & Equivalents was $671.0 million for Q2 2026 at Chemours, up from $563.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.2 billion in Q2 2022, with the low at $464.0 million in Q1 2025.
• Average Cash & Equivalents over 5 years is $800.7 million, with a median of $725.5 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents tumbled 40.87% in 2023, then soared 33.67% in 2026.
• Over 5 years, Cash & Equivalents stood at $1.1 billion in 2022, then grew by 9.17% to $1.2 billion in 2023, then plunged by 40.73% to $713.0 million in 2024, then fell by 6.03% to $670.0 million in 2025, then gained by 0.15% to $671.0 million in 2026.
• The last three Cash & Equivalents figures came in at $671.0 million (Q2 2026), $563.0 million (Q1 2026), and $670.0 million (Q4 2025), per Business Quant data.